Evidence map›Paper›PMID 33883559›Full record

ArticleNPJ vaccines2021

Intranasal powder live attenuated influenza vaccine is thermostable, immunogenic, and protective against homologous challenge in ferrets.

Jasmina M Luczo, Tatiana Bousse, Scott K Johnson, Cheryl A Jones, Nicholas Pearce, Carlie A Neiswanger, Min-Xuan Wang, Erin A Miller, Nikolai Petrovsky, David E Wentworth and 3 more

Open access · goldAbstract read
In one paragraph

Article in NPJ vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Monocyte-derived galectin-1Nature immunology · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Jasmina M LuczoCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.ORCID http://orcid.org/0000-0002-8036-110X
Tatiana BousseInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Scott K JohnsonCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
Cheryl A JonesCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
Nicholas PearceInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Carlie A NeiswangerCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
Min-Xuan WangUniversal Stabilization Technologies, Inc., San Diego, California, USA.
Erin A MillerUniversal Stabilization Technologies, Inc., San Diego, California, USA.
Nikolai PetrovskyCollege of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia.ORCID http://orcid.org/0000-0002-1580-5245
David E WentworthInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0002-5190-980X
Victor BronshteinUniversal Stabilization Technologies, Inc., San Diego, California, USA.
Mark PapaniaGlobal Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Stephen M TompkinsCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA. smt@uga.edu.ORCID http://orcid.org/0000-0002-1523-5588
University of Georgia · USCenters for Disease Control and Prevention · USUniversal Stabilization Technologies · USFlinders University · AU

Funding

Novel vaccine adjuvants to counter bioterrorist threatsU01AI061142 · NIAID · FLINDERS UNIVERSITY OF SOUTH AUSTRALIA · PI PETROVSKY, NIKOLAI · 2005 to 2009
$3.5M
PREP at University of GeorgiaR25GM109435 · NIGMS · UNIVERSITY OF GEORGIA · PI DOLAN, ERIN L, KLONOWSKI, KIMBERLY D. · 2014 to 2024
$3.4M
NIAID NIH HHS HHSN272200800039CNIAID NIH HHS HHSN272201400004CNIAID NIH HHS HHSN272201400008CNIAID NIH HHS HHSN272201400053CNIAID NIH HHS U01 AI061142NIGMS NIH HHS R25 GM109435
6 · The paper itself

Abstract

Influenza viruses cause annual seasonal epidemics and sporadic pandemics; vaccination is the most effective countermeasure. Intranasal live attenuated influenza vaccines (LAIVs) are needle-free, mimic the natural route of infection, and elicit robust immunity. However, some LAIVs require reconstitution and cold-chain requirements restrict storage and distribution of all influenza vaccines. We generated a dry-powder, thermostable LAIV (T-LAIV) using Preservation by Vaporization technology and assessed the stability, immunogenicity, and efficacy of T-LAIV alone or combined with delta inulin adjuvant (Advax™) in ferrets. Stability assays demonstrated minimal loss of T-LAIV titer when stored at 25 °C for 1 year. Vaccination of ferrets with T-LAIV alone or with delta inulin adjuvant elicited mucosal antibody and robust serum HI responses in ferrets, and was protective against homologous challenge. These results suggest that the Preservation by Vaporization-generated dry-powder vaccines could be distributed without refrigeration and administered without reconstitution or injection. Given these significant advantages for vaccine distribution and delivery, further research is warranted.

Identifiers

PMID33883559
PMCPMC8060263
OpenAlexW3156795320

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.